Drugs / CT120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05091541 | Oct 2021 → Oct 2024 overdue | B-cell non-Hodgkin lymphoma | Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-11-26 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory IASO Biotheraputics’ CT120 Granted Orphan Drug Designation by the U.S. FDA iasobio.com ↗
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicine announced today that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation (ODD) to the company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). |
| 2021-08-02 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials iasobio.com ↗
today announced the clearance from China’s National Medical Products Administration (NMPA) of two Initial New Drug (IND) applications for CT120 |
| 2021-06-01 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory Application for clinical trial of the 2nd indication of IASO Biotherapeutics’ fully human CD19/CD22 dual-targeted CAR-T drug accepted by NMPA iasobio.com ↗
This acceptance comes only one day after the acceptance of the drug’s first indication for the treatment of CD19/CD22 positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). |
| 2021-05-23 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory IASO Announced Acceptance of IND Application by NMPA for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy iasobio.com ↗
the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted (acceptance number CXSL2101070) the investigational new drug (IND) application for CT120 |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-26 | Nanjing IASO Biotechnology Co., Ltd. | IASO Biotheraputics’ CT120 Granted Orphan Drug Designation by the U.S. FDA iasobio.com ↗ |
| 2021-11-09 | Nanjing IASO Biotechnology Co., Ltd. | IASO Biotheraputics Completes Enrollment of First Patient in CT120’s Phase I/II Registrational Clinical Trial iasobio.com ↗ |
| 2021-08-02 | Nanjing IASO Biotechnology Co., Ltd. | IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials iasobio.com ↗ |
| 2021-06-01 | Nanjing IASO Biotechnology Co., Ltd. | Application for clinical trial of the 2nd indication of IASO Biotherapeutics’ fully human CD19/CD22 dual-targeted CAR-T drug accepted by NMPA iasobio.com ↗ |
| 2021-05-23 | Nanjing IASO Biotechnology Co., Ltd. | IASO Announced Acceptance of IND Application by NMPA for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy iasobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT120 | “CT120 is an autologous CD19/22 targeted CAR-T cells injection.” NCT05091541 ↗ |
| Modality | Cell therapy | “CT120 is an autologous CD19/22 targeted CAR-T cells injection.” NCT05091541 ↗ |
| Target | CD19 | “CT120 is an autologous CD19/22 targeted CAR-T cells injection.” NCT05091541 ↗ |